These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
460 related articles for article (PubMed ID: 9164314)
21. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. Montaner JS; Reiss P; Cooper D; Vella S; Harris M; Conway B; Wainberg MA; Smith D; Robinson P; Hall D; Myers M; Lange JM JAMA; 1998 Mar; 279(12):930-7. PubMed ID: 9544767 [TBL] [Abstract][Full Text] [Related]
22. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party. Eron JJ; Benoit SL; Jemsek J; MacArthur RD; Santana J; Quinn JB; Kuritzkes DR; Fallon MA; Rubin M N Engl J Med; 1995 Dec; 333(25):1662-9. PubMed ID: 7477218 [TBL] [Abstract][Full Text] [Related]
23. A randomized, open-label, comparative trial of zidovudine plus lamivudine versus zidovudine plus lamivudine plus didanosine in antiretroviral-naive HIV-1-infected Thai patients. Ungsedhapand C; Kroon ED; Suwanagool S; Ruxrungtham K; Yimsuan N; Sonjai A; Ubolyam S; Buranapraditkun S; Tiengrim S; Pakker N; Kunanusont C; Lange JM; Cooper DA; Phanuphak P J Acquir Immune Defic Syndr; 2001 Jun; 27(2):116-23. PubMed ID: 11404532 [TBL] [Abstract][Full Text] [Related]
24. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Beirn Community Programs for Clinical Research on AIDS. Saravolatz LD; Winslow DL; Collins G; Hodges JS; Pettinelli C; Stein DS; Markowitz N; Reves R; Loveless MO; Crane L; Thompson M; Abrams D N Engl J Med; 1996 Oct; 335(15):1099-106. PubMed ID: 8813040 [TBL] [Abstract][Full Text] [Related]
25. Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. North American HIV Working Party. Bartlett JA; Benoit SL; Johnson VA; Quinn JB; Sepulveda GE; Ehmann WC; Tsoukas C; Fallon MA; Self PL; Rubin M Ann Intern Med; 1996 Aug; 125(3):161-72. PubMed ID: 8686973 [TBL] [Abstract][Full Text] [Related]
26. An evaluation of HIV RNA and CD4 cell count as surrogates for clinical outcome. Delta Coordinating Committee and Virology Group. AIDS; 1999 Apr; 13(5):565-73. PubMed ID: 10203381 [TBL] [Abstract][Full Text] [Related]
27. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. Hammer SM; Katzenstein DA; Hughes MD; Gundacker H; Schooley RT; Haubrich RH; Henry WK; Lederman MM; Phair JP; Niu M; Hirsch MS; Merigan TC N Engl J Med; 1996 Oct; 335(15):1081-90. PubMed ID: 8813038 [TBL] [Abstract][Full Text] [Related]
28. Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals. North American Lamivudine HIV Working Group. Phillips AN; Eron J; Bartlett J; Kuritzkes DR; Johnson VA; Gilbert C; Johnson J; Keller A; Hill AM AIDS; 1997 Feb; 11(2):169-75. PubMed ID: 9030363 [TBL] [Abstract][Full Text] [Related]
29. Reductions in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy. Mathez D; Bagnarelli P; Gorin I; Katlama C; Pialoux G; Saimot G; Tubiana P; De Truchis P; Chauvin JP; Mills R; Rode R; Clementi M; Leibowitch J Antivir Ther; 1997 Jul; 2(3):175-83. PubMed ID: 11322272 [TBL] [Abstract][Full Text] [Related]
30. A randomized trial comparing regimens of four reverse transcriptase inhibitors given together or cyclically in HIV-1 infection--the Quattro Trial. Quattro Steering Committee. AIDS; 1999 Nov; 13(16):2209-17. PubMed ID: 10563706 [TBL] [Abstract][Full Text] [Related]
31. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903. Berenguer J; González J; Ribera E; Domingo P; Santos J; Miralles P; Angels Ribas M; Asensi V; Gimeno JL; Pérez-Molina JA; Terrón JA; Santamaría JM; Pedrol E; Clin Infect Dis; 2008 Oct; 47(8):1083-92. PubMed ID: 18781872 [TBL] [Abstract][Full Text] [Related]
32. Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients. Staszewski S; Miller V; Rehmet S; Stark T; De Crée J; De Brabander M; Peeters M; Andries K; Moeremans M; De Raeymaeker M; Pearce G; Van den Broeck R; Verbiest W; Stoffels P AIDS; 1996 May; 10(5):F1-7. PubMed ID: 8724034 [TBL] [Abstract][Full Text] [Related]
33. Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET Study. Henry K; Wallace RJ; Bellman PC; Norris D; Fisher RL; Ross LL; Liao Q; Shaefer MS; J Infect Dis; 2001 Feb; 183(4):571-8. PubMed ID: 11170982 [TBL] [Abstract][Full Text] [Related]
34. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients. Delfraissy JF; Flandre P; Delaugerre C; Ghosn J; Horban A; Girard PM; Norton M; Rouzioux C; Taburet AM; Cohen-Codar I; Van PN; Chauvin JP AIDS; 2008 Jan; 22(3):385-93. PubMed ID: 18195565 [TBL] [Abstract][Full Text] [Related]
35. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. Collier AC; Coombs RW; Schoenfeld DA; Bassett RL; Timpone J; Baruch A; Jones M; Facey K; Whitacre C; McAuliffe VJ; Friedman HM; Merigan TC; Reichman RC; Hooper C; Corey L N Engl J Med; 1996 Apr; 334(16):1011-7. PubMed ID: 8598838 [TBL] [Abstract][Full Text] [Related]
36. Virologic and CD4 cell response to zidovudine or zidovudine and lamivudine following didanosine treatment of human immunodeficiency virus infection. Katzenstein DA; Hughes MD; Albrecht M; Liou SH; Murphy R; Balfour H; Para M; Hammer S; AIDS Res Hum Retroviruses; 2001 Feb; 17(3):203-10. PubMed ID: 11177402 [TBL] [Abstract][Full Text] [Related]
37. Tenofovir: new indication. For first-line antiretroviral therapy: wait and see. Prescrire Int; 2004 Oct; 13(73):180-2. PubMed ID: 15499699 [TBL] [Abstract][Full Text] [Related]
38. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial. Petra Study Team Lancet; 2002 Apr; 359(9313):1178-86. PubMed ID: 11955535 [TBL] [Abstract][Full Text] [Related]
39. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team. Pialoux G; Raffi F; Brun-Vezinet F; Meiffrédy V; Flandre P; Gastaut JA; Dellamonica P; Yeni P; Delfraissy JF; Aboulker JP N Engl J Med; 1998 Oct; 339(18):1269-76. PubMed ID: 9791142 [TBL] [Abstract][Full Text] [Related]
40. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. Gulick RM; Mellors JW; Havlir D; Eron JJ; Gonzalez C; McMahon D; Richman DD; Valentine FT; Jonas L; Meibohm A; Emini EA; Chodakewitz JA N Engl J Med; 1997 Sep; 337(11):734-9. PubMed ID: 9287228 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]